Polypodium leucotomos

Polypodium leucotomos is an extract from a tropical fern, taken as an oral capsule for sun protection from the inside. Most people use it because they get melasma or stubborn pigmentation that flares with sun exposure, they have a sun-triggered rash like polymorphic light eruption that ruins the first beach week of every summer, or they want a low-effort daily layer of UV protection on top of

SPF 50 and clothing.

It is not a sunscreen replacement. It does not absorb UV, it does not have an SPF, and you will still burn without topical protection. What it does is reduce the downstream damage UV causes once it reaches your skin, by mopping up the free radicals UV generates and toning down the inflammatory cascade that follows.

Deep-dive

The extract comes from the leaves of a Central and South American fern (taxonomically now reclassified as Phlebodium aureum, but the supplement world still calls it Polypodium leucotomos, or PLE). The active fraction is a mix of phenolic acids, mainly ferulic, caffeic, p-coumaric, vanillic, and chlorogenic acid, all polyphenols with established antioxidant activity. A 2005 ScienceDirect study characterising the extract found ferulic and caffeic acids carried most of the antioxidant weight in vitro, and that the phenolics are absorbed across an intestinal barrier model and metabolised through hepatic monooxygenases.

Mechanistically, PLE does not block UV at the skin surface. It works systemically once absorbed. The phenolics, sitting in skin cells reached via circulation, neutralise the reactive oxygen species that UV exposure generates inside keratinocytes and fibroblasts. A 2016 mechanistic review summarised the in vitro and in vivo work showing PLE reduces UV- and ROS-induced DNA damage, blunts lipid peroxidation, inhibits the inflammatory transcription factors AP-1 and NF-kB, suppresses UV-induced nitric oxide release, and preserves endogenous antioxidant enzymes. In skin terms, that translates to fewer sunburn cells, fewer cyclobutane pyrimidine dimers (a marker of UV-induced DNA damage), and less of the matrix metalloproteinase activity that breaks down collagen after sun exposure.

Direct UV response in healthy skin. This is the cleanest evidence. A 2017 randomised controlled study in 22 fair-skinned volunteers irradiated subjects with UVB, UVA1, and visible light, then put them on 240 mg of PLE twice daily and re-irradiated them. The minimal erythema dose (the UV dose required to redden skin) increased, sunburn cell counts dropped, and DNA damage markers were reduced. A 2015 double-blind RCT in healthy adults at the same dose of 240 mg twice daily for 60 days found that the placebo group was significantly more likely to sunburn (8 vs 2 subjects), with no changes in safety blood work. A 2025 8-week trial using a syrup containing PLE plus red orange extract and a few vitamins found gradual increases in MED and reductions in UVB-induced erythema over 8 weeks, becoming statistically significant by week 8 but not at week 2. The pattern across studies: PLE shifts the burn threshold modestly upward, but the effect is built gradually and is most visible against an actual UV challenge.

Melasma. This is one of the better real-world use cases. A 2018 randomised, double-blind, placebo-controlled trial in 40 Asian women with melasma using 4% hydroquinone cream plus SPF 50, found that adding 480 mg of oral PLE per day for 12 weeks produced significantly greater improvements in the modified melasma severity index (mMASI) than placebo. A 2014 review of pigmentary disorders covers the broader picture across vitiligo, melasma, and post-inflammatory hyperpigmentation. A 2023 scoping review and meta-analysis included PLE among the antioxidants with a signal in melasma, though noted variability in effect sizes across small trials. The honest read: as a standalone melasma treatment PLE is not enough, but as an adjunct to hydroquinone or other depigmenting topicals plus aggressive sun protection, it adds something measurable.

Polymorphic light eruption (PMLE) and other photodermatoses. PMLE is the most common immune-mediated sun-triggered rash, more frequent in women, often appearing in the first sun exposures of spring. PLE has the most consistent evidence here outside of straight UV protection. An open-label trial in 35 PMLE patients using artificial photoprovocation found that taking PLE between two provocation sessions reduced or prevented the typical PMLE lesions in most patients. PLE is referenced in current StatPearls clinical guidance for PMLE as an oral photoprotective option with emerging evidence alongside niacinamide. For people with solar urticaria, actinic prurigo, or other idiopathic photodermatoses, the evidence is thinner but the same mechanism applies and dermatologists prescribe it in this context.

Vitiligo (as adjunct to phototherapy). Three small randomised double-blind placebo-controlled trials, summarised in the 2014 pigmentary disorders review and the 2021 dermatologic applications review, found that adding PLE to narrowband UVB or PUVA phototherapy improved repigmentation rates compared to phototherapy alone. The mechanism is plausibly oxidative-stress related, since melanocytes in vitiligo are sensitive to ROS. Useful adjunct, not a standalone treatment.

Photoaging and skin cancer risk. The mechanism (reduced DNA damage, MMP suppression, anti-inflammatory) is consistent with a long-term photoaging and chemoprevention angle, and the 2014 literature review and a 2023 review on oncodermatology applications frame it that way. But there are no long-term randomised trials in humans showing that daily PLE reduces actinic keratoses, basal/squamous cell carcinoma, or melanoma incidence. The biological case is reasonable, the human outcome data is not there yet. Treat the photoaging and skin-cancer-prevention story as plausible mechanism rather than established benefit.

Brand matters more than usual. Most of the published trials use one specific extract, Fernblock (sold consumer-side as Heliocare). A 2019 head-to-head analysis comparing six different PLE formulations on the market found significant differences in polyphenol content and photoprotective activity between brands, with only one brand consistently matching the trial-grade extract. This matters because the active fraction depends on the part of the fern used (leaves vs rhizome), the extraction method (aqueous vs other solvents), and standardisation of phenolic content. Generic "polypodium leucotomos" capsules from supplement aisles are not interchangeable with the trial-grade extract.

Women. Trials have generally included both sexes, and the photoprotective effect looks similar by sex with no dose adjustment needed. There is more female-specific use because the conditions it treats, particularly melasma and PMLE, disproportionately affect women. Melasma is heavily female-skewed (the relationship with oestrogen and pregnancy is well established) and PMLE is more common in women. The Asian melasma trial was conducted entirely in women and is one of the cleanest pieces of evidence for PLE in this database. Skip it in pregnancy and breastfeeding, not because of documented harm but because the safety data does not exist and melasma management during pregnancy is better handled with sun avoidance and SPF anyway.

Anecdotally, the picture in user communities tracks reasonably well with the trials. People with melasma and PMLE most often report meaningful benefit, often calling out that summer trips and outdoor weekends became significantly less of a problem. Healthy users without a photodermatosis report a more subtle effect, typically that they tan a little more evenly, redden a little less, or notice a slightly slower burn during a long day in strong sun. Reports are most split among people taking it for general antiaging or vague "skin health," where the benefit is hard to perceive without a UV challenge, and many users in that group end up dropping it because they cannot feel anything. That tracks with the mechanism, the effect is mostly visible against UV exposure, not against a normal indoor day.

Dosage:

Standard daily dose is 240 mg twice daily (480 mg/day total), which is what the well-controlled photoprotection and melasma trials use. A single 480 mg dose in the morning is acceptable if compliance is the issue, but split dosing keeps blood levels more consistent across the day

For a single high-UV exposure (beach day, ski day, long hike in strong sun, tropical travel), take 240-480 mg about 30-60 minutes before going out. The phenolics reach skin within hours, so timing it before exposure matters more than dose size

For melasma, PMLE, or vitiligo on phototherapy, run 480 mg/day continuously through the high-UV months or the full treatment course. Most trials run 8-12 weeks before assessing response, so do not judge it earlier than that

Brand matters. Fernblock-based products (Heliocare is the consumer brand and is the one used in nearly all the human trials) are the only formulation with a body of trial evidence behind them. Generic PLE capsules are not equivalent, the head-to-head formulation study found large between-brand differences in active content. If you are going to take this, buy the trial-grade extract

Timing within the day: take with food. The phenolic acids absorb better with a meal and GI tolerance is better. No need for evening timing, the protective effect is whole-body and not tied to time of day

It is not a replacement for sunscreen.
SPF 50, shade, and clothing still do the bulk of the work. PLE is an adjunct that reduces the damage that gets through. The trials all use it on top of topical sun protection, not instead of it

Stacks: pairs naturally with
Niacinamide (separate oral photoprotective and skin-cancer-chemoprevention evidence) and with topical
Vitamin C under sunscreen for a layered antioxidant approach.
Astaxanthin covers similar ground via a different mechanism (membrane-spanning carotenoid antioxidant); running both is reasonable but not necessary

Here's what you can expect:

Nothing acute. PLE is not a compound you feel. The honest timeline depends on what you are taking it for.

For general UV protection: the first thing you may notice is that during a day in strong sun you tan a little more evenly and redden a little less. This shows up best when you actually compare a sunny weekend on PLE to one off it. Studies measure this as a higher minimal erythema dose, and the effect builds over weeks rather than appearing immediately. After 8 weeks of daily use the effect is more consistent than after 2.

For melasma: improvement is gradual, on the order of 8-12 weeks layered on top of hydroquinone or similar topicals and strict sun protection. Without those, expect little. With them, the trial evidence is that PLE adds meaningfully to what the topicals alone achieve.

For PMLE: the practical effect is that the rash either does not appear during the high-UV exposures that normally trigger it, or appears later and less severely. People who run it through the spring and summer often describe it as the difference between losing the first week of every holiday and not. Start it a couple of weeks before high exposure.

With long-term daily use, the subjective sense of "doing something" can fade because there is no overt feel to the compound. The protection is happening at the cellular level and only shows up in contexts that test it.

Side effects & risks:

Very well tolerated across all human trials. The 60-day RCT at 480 mg/day in healthy adults monitored blood counts, comprehensive metabolic panel, and coagulation, and found no changes versus placebo. This is one of the cleaner safety profiles in this database

Mild GI upset (nausea, stomach discomfort, occasional loose stools) is the most common side effect, usually resolves by taking it with food or splitting the dose

Mild itching or transient skin rash has been reported occasionally and resolves on stopping

It is not a substitute for sunscreen. This is the most important practical point, not a side effect strictly, but worth repeating because the marketing implies otherwise. You will still burn without
SPF 50 and clothing. PLE reduces damage that gets through, it does not stop UV from getting through

Pregnancy and breastfeeding: skip it. No documented harm, but also no adequate safety data, and there is no strong reason to add it during these periods when the simpler intervention (shade, SPF, hats) is preferred anyway

Long-term safety data thins out past 6 months of daily use. The longest controlled trials run a few months. There are decades of clinical use, especially in Spain where it has been prescribed for photodermatoses for many years, with no safety signals emerging, but well-controlled multi-year data is limited

Drug interactions: the phenolics are metabolised by hepatic CYP450 enzymes, so a theoretical interaction with drugs heavily reliant on the same pathway exists, but no clinically significant interactions have been reported in the literature. If you are on multiple prescription medications metabolised by CYP3A4 or related enzymes, mention it to your prescriber

Children: has been used short-term in dermatologic conditions in children at adjusted doses, but supplementation in healthy children is not indicated and not necessary

Sold as a dietary supplement in most countries without prescription.